1Q VC Data: What Just Happened?

The National Venture Capital Association recently released data on first-quarter investment activity, which always makes for an interesting read, at least on long plane rides. Point of fact, this past quarter was exceptional in many ways—and arguably somewhat unexpected. The headlines read that $9.5 billion was invested in 951 companies, an amount we have not seen since the fateful second quarter of 2001. But it is what is beneath the headlines, buried in the reams of data, which paints a more nuanced picture.

Undoubtedly, the level of investment over the first 90 days of 2014 was unprecedented. In last year’s fourth quarter and first quarter, the amounts were $8.4 billion in 1,112 companies and $6 billion in 916 companies, respectively. Clearly, the stepped-up investment pace throughout 2013 extended into 2014 and tracked the increased liquidity VCs witnessed along the way. Given the marked public stock market volatility which set in this past February, it would not be surprising to see activity tempered over the next few quarters, suggesting that we probably are not on an annual investment pace of approximately $38 billion for 2014. For context, annual investment activity from 2011-2013 averaged about $28 billion.

Overall, certain important themes are emerging in the most recent quarterly data: VCs are clearly investing in later-stage companies, VCs are investing in businesses that have meaningfully less technology and development risk, and round sizes have spiked, most notably by “mega rounds” of hundreds of millions of dollars—which probably skews the data somewhat.

So what jumped out at me?

—Dramatic decline in seed investing: Only $125 million was invested in 41 seeds (average deal size $3 million) in the first quarter, as compared with $347 million in 69 companies (average size $5 million) in the prior quarter, which is a decrease of 64 percent. The advent of the micro-VC and “super angel” investor from a few years ago may be running its course.

—Where did the seeds go? Early-round financings were $2.9 billion (451 companies, average size $6.4 million) of the activity, which is a meaningful step up from $1.6 billion (420 companies, average size $3.7 million) in the same quarter last year. Not surprisingly, many of the seeds from prior periods have graduated onto the next phase of growth.

—Expansion-stage financings really spiked up: In the first quarter of 2014, $3.9 billion was invested in 274 companies (average size $14.3 million), which was over 40 percent of all investment activity for the quarter, compared with $2.1 billion in 239 companies (average size $8.6 million) in the prior-year period. Quite clearly, VCs are doubling down and supporting those seeds, which appear to be breaking out with larger rounds.

—The software category sucked the air out of the room: Software was 42 percent of all financing activity and far and away the largest of the 17 categories tracked. In the first quarter, $4 billion was invested in 414 software companies (average size $9.7 million), compared with $2.3 billion in 361 companies a year ago. Arguably, this activity came at the expense of other categories such as telecom, semiconductor, networking and equipment, and electronics, which barely registered this past quarter (only $20 million was invested in networking and equipment, for instance).

—Services investing surged: All categories of services (business, IT, financial, and consumer) more than doubled from a year ago and measured $1.7 billion invested in 126 companies (average size $13.4 million). This is somewhat surprising given the historic VC aversion to services business models, as they “don’t scale” and have lower gross margins. Are VCs investing in safer companies? Clearly they have all but avoided capital-intensive hardware businesses.

—Healthcare held its own: In the first quarter, $1.7 billion was invested in 182 companies, compared with $1.5 billion in 182 companies and $1.9 billion in 252 companies in the first quarter and fourth quarter of 2013, respectively. Overall, though, healthcare (biotech, medical devices, and healthcare services) captured only 15 percent of all dollars invested.

—Which category was the dark horse? Over $250 million was invested in retailing this past quarter, compared with $17 million in the same period last year.

The shuffling between stage of investing and industry categories is always illuminating. VCs seem to be investing later to get closer to liquidity, perhaps to bolster

Author: Michael A. Greeley

Michael is a General Partner at Flare Capital Partners. Prior to co-founding Flare Capital Partners, Michael was the founding General Partner of Flybridge Capital Partners where he led the firm’s healthcare investments. Current and prior board seats include BlueTarp Financial, Circulation, EndoGastric Solutions, Explorys, Functional Neuromodulation, HealthVerity, Iora Health, MicroCHIPS, Nuvesse, PolyRemedy, Predictive Biosciences, Predilytics, T2 Biosystems, TARIS Biomedical, VidSys and Welltok. Previously, Michael focused on emerging-growth company financings with Polaris Venture Partners, was a senior vice president and founding partner of GCC Investments, and held positions at Wasserstein Perella & Co., Morgan Stanley & Co. and Credit Suisse First Boston. Michael currently serves as chairman of the Entrepreneurship Committee of the Massachusetts Information Collaborative and on the Investment Committee for the Partners Innovation Fund and Massachusetts Eye & Ear Infirmary. Michael also serves on the Industry Advisory Board of the Cleveland Clinic and Boston Children’s Hospital, as well as serving on several other boards including the New England Investors’ Committee of Capital Innovation. He was the former chairman of the New England Venture Capital Association and on the Executive Committee of the board of the National Venture Capital Association. Named by the Boston Globe as the “Go-To” investor for life sciences, healthcare and medical devices and a Mass High Tech All-Star, Michael earned a B.A. with honors in chemistry from Williams College and an M.B.A. from Harvard Business School. Michael authors a blog focused on venture capital, innovation and healthcare at www.ontheflyingbridge.com.